Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Lucence Dx Liquid Biopsy Tech Detects Structural Rearrangements, Breast Cancer Mutations

Lucence Dx Liquid Biopsy Tech Detects Structural Rearrangements, Breast Cancer Mutations

May 29, 2020
|
John Gilmore
Premium

NEW YORK – As part of its push to develop a range of liquid biopsy assays for cancer detection, Lucence Diagnostics has completed two studies that demonstrate the ability of its amplicon-based next-generation sequencing platform, AmpliMark, to detect structural rearrangements (SR) in lung cancer as well as common cancer mutations in breast patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

European Regulators Begin Review of Sputnik V

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Irish Funding Agency Seeks Boost

Science reports that Science Foundation Ireland is seeking annual budget increases.

Lower Fees Sought

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

Nature Papers Examine Peregrine Falcon Migration Patterns, Tool to Search Single-Cell Data

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

What's Popular?

In Molecular Diagnostics

  1. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

  2. C2i Genomics Acquires Sequencing Lab QNA Dx

  3. Qiagen MDx Sample Processing Platform Garners CE-IVD Mark

  4. Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

  5. Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.